
Title:
Non-Hodgkin lymphoma
Text:
Type of cancer of lymph nodes



Medical condition.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}Non-Hodgkin lymphomaOther namesNon-Hodgkin diseaseMicrograph of mantle cell lymphoma, a type of non-Hodgkin lymphoma. Terminal ileum. H&E stain.SpecialtyHematology and oncologySymptomsEnlarged lymph nodes, fever, night sweats, weight loss, tiredness, itching[1]Usual onset65–75 years old[2]Risk factorsPoor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity, Epstein-Barr virus infection[1][3]Diagnostic methodBone marrow or lymph node biopsy[1]TreatmentChemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery, watchful waiting[1]PrognosisFive-year survival rate 71% (USA)[2]Frequency4.3 million (affected during 2015)[4]Deaths231,400 (2015)[5]
Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas.[1] Symptoms include enlarged lymph nodes, fever, night sweats, weight loss and tiredness.[1] Other symptoms may include bone pain, chest pain or itchiness.[1] Some forms are slow-growing, while others are fast-growing.[1]
Lymphomas are types of cancer that develop from lymphocytes, a type of white blood cell.[2] Risk factors include poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity, and Epstein–Barr virus infection.[1][3] The World Health Organization  classifies lymphomas into five major groups, including one for Hodgkin lymphoma.[6] Within the four groups for NHL are over 60 specific types of lymphoma.[7][8] Diagnosis is by examination of a bone marrow or lymph node biopsy.[1] Medical imaging is done to help with cancer staging.[1]
Treatment depends on whether the lymphoma is slow- or fast-growing and if it is in one area or many areas.[1] Treatments may include chemotherapy, radiation, immunotherapy, targeted therapy, stem-cell transplantation, surgery, or watchful waiting.[1] If the blood becomes overly thick due to high numbers of antibodies, plasmapheresis may be used.[1] Radiation and some chemotherapy, however, increase the risk of other cancers, heart disease, or nerve problems over the subsequent decades.[1]
In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 died.[4][5] In the United States, 2.1% of people are affected at some point in their life.[2] The most common age of diagnosis is between 65 and 75 years old.[2] The five-year survival rate in the United States is 71%.[2]

Contents

1 Signs and symptoms
2 Causes

2.1 Familial component
2.2 HIV/AIDS


3 Treatment

3.1 Chemotherapy
3.2 Treatment complications
3.3 Other


4 Prognosis
5 Epidemiology

5.1 Australia
5.2 Canada
5.3 United Kingdom
5.4 United States


6 History
7 References
8 External links



Signs and symptoms[edit]
The signs and symptoms of non-Hodgkin lymphoma vary depending upon its location within the body. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow growing, while others are fast growing.[1] Enlarged lymph nodes may cause lumps to be felt under the skin when they are close to the surface of the body. Lymphomas in the skin may also result in lumps, which are commonly itchy, red, or purple. Lymphomas in the brain can cause weakness, seizures, problems with thinking, and personality changes.[medical citation needed]
While an association between non-Hodgkin lymphoma and endometriosis has been described,[9] these associations are tentative.[10]

Causes[edit]
The many different forms of lymphoma probably have different causes. These possible causes and associations with at least some forms of NHL include:

Infectious agents:
Epstein–Barr virus: associated with Burkitt's lymphoma, Hodgkin lymphoma, follicular dendritic cell sarcoma, extranodal NK-T-cell lymphoma and diffuse large B-cell lymphoma.[11]
Human T-cell leukemia virus: associated with adult T-cell lymphoma.
Helicobacter pylori: associated with gastric lymphoma.
HHV-8: associated with primary effusion lymphoma, multicentric Castleman disease.
Hepatitis C virus: associated with splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma.[12]
HIV infection.[13]
Some chemicals, like polychlorinated biphenyls (PCBs),[14][15][16] diphenylhydantoin, dioxin, and phenoxy herbicides.
Medical treatments, like radiation therapy and chemotherapy.
Genetic diseases, like Klinefelter syndrome, Chédiak–Higashi syndrome, ataxia–telangiectasia syndrome.
Autoimmune diseases, like Sjögren syndrome, celiac disease, rheumatoid arthritis, and systemic lupus erythematosus.[17][18]
Bone trauma and microfractures associated with diffuse large B-cell lymphoma originating in bone marrow.[19][20]
Implants, made from hard metals or silicone, associated with anaplastic large cell lymphoma.[21][22]
Familial component[edit]
Familial lymphoid cancer is rare. The familial risk of lymphoma is elevated for multiple lymphoma subtypes, suggesting a shared genetic cause. However, a family history of a specific subtype is most strongly associated with risk for that subtype, indicating that these genetic factors are subtype-specific. Genome-wide association studies  have successfully identified 67 single-nucleotide polymorphisms  from 41 loci, most of which are subtype specific.[23]

HIV/AIDS[edit]
The Centers for Disease Control and Prevention (CDC) included certain types of non-Hodgkin lymphoma as AIDS-defining cancers in 1987.[24] Immune suppression rather than HIV itself is implicated in the pathogenesis of this malignancy, with a clear correlation between the degree of immune suppression and the risk of developing NHL. Additionally, other retroviruses, such as HTLV, may be spread by the same mechanisms that spread HIV, leading to an increased rate of co-infection.[25] The natural history of HIV infection has been greatly changed over time. As a consequence, rates of non-Hodgkin lymphoma (NHL) in people infected with HIV has significantly declined in recent years.[13]

Treatment[edit]
The traditional treatment of NHL includes chemotherapy, radiotherapy, and stem-cell transplants.[26][27] There have also been developments in immunotherapy used in the treatment of NHL.[28]

Chemotherapy[edit]
The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab.[29]

Treatment complications[edit]
If participants receive stem-cell transplants, they can develop a graft-versus-host disease. When compared with placebo for treating immune mediated inflammation post transplantation and in autoimmunity, mesenchymal stromal cells (MSCs) may reduce the all-cause mortality if they are used for a therapeutic reason.[30] Moreover, the therapeutic use of MSCs may increase the complete response of acute and chronic GvHD, but the evidence is very uncertain.[30] The evidence suggests that MSCs for prophylactic reason result in little to no difference in the all-cause mortality, in the relapse of malignant diseases, and in the incidence of acute GvHD.[30] The evidence suggests that MSCs for prophylactic reason reduce the incidence of chronic GvHD.[30]
Platelet transfusions may be necessary for those who receive chemotherapy or undergo a stem cell transplantation due to the higher risk for bleeding. When comparing therapeutic/non-prophylactic platelet transfusions to prophylactic platelet transfusions there is little to no difference in the mortality secondary to bleeding and they may result in a slight reduction in the number of days on which a significant bleeding event occurred.[31] The evidence suggests that therapeutic platelet transfusions result in a large increase in the number of people with at least one significant bleeding event and they likely result in a large reduction in the number of platelet transfusions.[31][32]

Other[edit]
It is not clear if including aerobic physical exercise, in addition to the standard treatment for adult patients with haematological malignancies, is effective at reducing anxiety and serious adverse effects.[33] Aerobic physical exercises may result in little to no difference in the mortality, in the quality of life and in the physical functioning.[33] These exercises may result in a slight reduction in depression and most likely reduce fatigue.[33]

Prognosis[edit]
Prognosis depends on the subtype, the staging, a person's age, and other factors. Across all subtypes, 5-year survival for NHL is 71%, ranging from 81% for Stage 1 disease to 61% for Stage 4 disease.[34]

Epidemiology[edit]
Globally, as of 2010, there were 210,000 deaths, up from 143,000 in 1990.[35]
Rates of non-Hodgkin lymphoma increase steadily with age.[17] Up to 45 years NHL is more common among males than females.[36]

Australia[edit]
With over 6,000 people being diagnosed yearly, NHL is the fifth most common cancer in Australia.[37]

Canada[edit]
In Canada, NHL is the fifth most common cancer in males and sixth most common cancer in females. The lifetime probability of developing a lymphoid cancer is 1 in 44 for males, and 1 in 51 for females.[38]

United Kingdom[edit]
On average, according to data for the 2014–2016 period, around 13,900 people are diagnosed with NHL yearly. It is the sixth most common cancer in the UK, and is the eleventh most common cause of cancer death accounting for around 4,900 deaths per year.[39]

United States[edit]
Age adjusted data from 2012 to 2016 shows about 19.6 cases of NHL per 100,000 adults per year, 5.6 deaths per 100,000 adults per year, and around 694,704 people living with non-Hodgkin lymphoma. About 2.2 percent of men and women will be diagnosed with NHL at some point during their lifetime.[40]
The American Cancer Society lists non-Hodgkin lymphoma as one of the most common cancers in the United States, accounting for about 4% of all cancers.[41]

History[edit]
While consensus was rapidly reached on the classification of Hodgkin lymphoma, there remained a large group of very different diseases requiring further classification. The Rappaport classification, proposed by Henry Rappaport in 1956 and 1966, became the first widely accepted classification of lymphomas other than Hodgkin. Following its publication in 1982, the Working Formulation became the standard classification for this group of diseases. It introduced the term non-Hodgkin lymphoma or NHL and defined three grades of lymphoma.[citation needed]
NHL consists of many different conditions that have little in common with each other. They are grouped by their aggressiveness. Less aggressive non-Hodgkin lymphomas are compatible with a long survival while more aggressive non-Hodgkin lymphomas can be rapidly fatal without treatment. Without further narrowing, the label is of limited usefulness for people or doctors. The subtypes of lymphoma are listed there.[citation needed]
Nevertheless, the Working Formulation and the NHL category continue to be used by many. To this day, lymphoma statistics are compiled as Hodgkin's versus non-Hodgkin lymphomas by major cancer agencies, including the US National Cancer Institute in its SEER program, the Canadian Cancer Society and the IARC.[citation needed]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c d e f g h i j k l m n o p .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version". NCI. 3 August 2016. Archived from the original on 16 August 2016. Retrieved 13 August 2016.

^ Jump up to: a b c d e f "SEER Stat Fact Sheets: Non-Hodgkin Lymphoma". NCI. April 2016. Archived from the original on 6 July 2014. Retrieved 13 August 2016.

^ Jump up to: a b World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 2.4, 2.6. ISBN 978-9283204299.

^ Jump up to: a b GBD 2015 Mortality and Causes of Death Collaborators (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282. {{cite journal}}: |author= has generic name (help)

^ Jump up to: a b GBD 2015 Mortality and Causes of Death Collaborators (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281. {{cite journal}}: |author= has generic name (help)

^ "Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version". NCI. 1 June 2016. Archived from the original on 12 August 2016. Retrieved 13 August 2016.

^ "Different types of non Hodgkin lymphoma". Cancer Research UK. Archived from the original on 14 August 2016. Retrieved 13 August 2016.

^ Bope ET, Kellerman RD (2015). Conn's Current Therapy 2016. Elsevier Health Sciences. p. 878. ISBN 9780323355353. Archived from the original on 10 September 2017.

^ Audebert A (April 2005). "[Women with endometriosis: are they different from others?]". Gynécologie, Obstétrique & Fertilité (in French). 33 (4): 239–46. doi:10.1016/j.gyobfe.2005.03.010. PMID 15894210.

^ Somigliana E, Vigano' P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P (May 2006). "Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence". Gynecologic Oncology. 101 (2): 331–41. doi:10.1016/j.ygyno.2005.11.033. PMID 16473398.

^ Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K (2009). "Spectrum of Epstein-Barr virus-related diseases: A pictorial review". Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526. S2CID 6970917.

^ Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013). "Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management". Journal of Hepatology. 59 (1): 169–177. doi:10.1016/j.jhep.2013.03.018. PMID 23542089.

^ Jump up to: a b Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B,  et al. (October 2012). "Non-AIDS-defining cancers among HIV-infected people". European Review for Medical and Pharmacological Sciences. 16 (10): 1377–88. PMID 23104654.

^ Kramer S, Hikel SM, Adams K, Hinds D, Moon K (2012). "Current Status of the Epidemiologic Evidence Linking Polychlorinated Biphenyls and Non-Hodgkin Lymphoma, and the Role of Immune Dysregulation". Environmental Health Perspectives. 120 (8): 1067–75. doi:10.1289/ehp.1104652. PMC 3440083. PMID 22552995.

^ Zani C, Toninelli G, Filisetti B, Donato F (2013). "Polychlorinated biphenyls and cancer: an epidemiological assessment". J. Environ. Sci. Health C. 31 (2): 99–144. doi:10.1080/10590501.2013.782174. PMID 23672403. S2CID 5294247.

^ Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K (2013). "Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls". Lancet Oncology. 14 (4): 287–288. doi:10.1016/s1470-2045(13)70104-9. PMID 23499544.

^ Jump up to: a b Tobias J, Hochhauser D (2015). Cancer and its Management (7th ed.). Wiley-Blackwell. ISBN 9781118468715.

^ Arnold S Freedman, Lee M Nadler (2000). "Chapter 130: Non–Hodgkin's Lymphomas".  In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds.). Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ont: B.C. Decker. ISBN 1-55009-113-1. Archived from the original on 10 September 2017.

^ Subik, M. Kristina; Herr, Megan; Hutchison, Robert E.; Kelly, Jennifer; Tyler, Wakenda; Merzianu, Mihai; Burack, W. Richard (November 2014). "A Highly Curable Lymphoma Occurs Preferentially in the Proximal Tibia of Young Patients". Modern Pathology. 27 (11): 1430–1437. doi:10.1038/modpathol.2014.51. ISSN 0893-3952. PMC 4201907. PMID 24743213.

^ Stein, M. E.; Lewis, D. C.; Gershuny, A. R.; Quigley, M. M.; Zaidan, J.; Danieli, N. Siegelmann; Whelan, J.; Subramanian, R. (April 2003). "Trauma as an etiologic factor of primary bone lymphoma: a report of 4 cases". Journal of B.U.ON. 8 (2): 163–166. ISSN 1107-0625. PMID 17472245.

^ Palraj, Bharath; Paturi, Anil; Stone, Ross G.; Alvarez, Harold; Sebenik, Matjaz; Perez, Maria T.; Bush, Larry M. (1 November 2010). "Soft Tissue Anaplastic Large T-Cell Lymphoma Associated with a Metallic Orthopedic Implant: Case Report and Review of the Current Literature". The Journal of Foot and Ankle Surgery. 49 (6): 561–564. doi:10.1053/j.jfas.2010.08.009. ISSN 1067-2516. PMID 20870426.

^ Popplewell, Leslie; Chang, Karen; Olevsky, Olga; Nademanee, A.; Forman, Stephen (16 November 2004). "Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants". Blood. 104 (11): 4563. doi:10.1182/blood.V104.11.4563.4563. ISSN 0006-4971.

^ Cerhan JR, Slager SL (November 2015). "Familial predisposition and genetic risk factors for lymphoma". Blood. 126 (20): 2265–73. doi:10.1182/blood-2015-04-537498. PMC 4643002. PMID 26405224.

^ Centers for Disease Control (CDC) (August 1987). "Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases" (PDF). MMWR Supplements. 36 (1): 1S–15S. PMID 3039334. Archived (PDF) from the original on 9 June 2017.

^ Lee B, Bower M, Newsom-Davis T, Nelson M (2010). "HIV-related lymphoma". HIV Therapy. 4 (6): 649–659. doi:10.2217/hiv.10.54. ISSN 1758-4310.

^ "Non-Hodgkin lymphoma". Cancer Council Australia. 22 March 2019. Retrieved 23 August 2019.

^ "Non-Hodgkin Lymphoma Treatment". American Cancer Society. 2019. Retrieved 23 August 2019.

^ "Immunotherapy for Non-Hodgkin Lymphoma". American Cancer Society. 2019. Retrieved 23 August 2019.

^ "Treating B-Cell Non-Hodgkin Lymphoma". American Cancer Society. 2019. Retrieved 23 August 2019.

^ Jump up to: a b c d Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, Girdlestone J,  et al. (Cochrane Haematological Malignancies Group) (January 2019). "Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition". The Cochrane Database of Systematic Reviews. 1: CD009768. doi:10.1002/14651858.CD009768.pub2. PMC 6353308. PMID 30697701.

^ Jump up to: a b Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle N,  et al. (Cochrane Haematological Malignancies Group) (May 2012). "Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation". The Cochrane Database of Systematic Reviews (5): CD004269. doi:10.1002/14651858.CD004269.pub3. PMID 22592695.

^ Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF,  et al. (Cochrane Haematological Malignancies Group) (November 2015). "Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation". The Cochrane Database of Systematic Reviews (11): CD010983. doi:10.1002/14651858.CD010983.pub2. PMC 4717525. PMID 26576687.

^ Jump up to: a b c Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N,  et al. (Cochrane Haematological Malignancies Group) (January 2019). "Aerobic physical exercise for adult patients with haematological malignancies". The Cochrane Database of Systematic Reviews. 1: CD009075. doi:10.1002/14651858.CD009075.pub3. PMC 6354325. PMID 30702150.

^ "Non-Hodgkin's Lymphoma Diagnosis, Treatment, Symptoms & Causes". MedicineNet. Retrieved 27 May 2020.

^ Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY,  et al. (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. hdl:10536/DRO/DU:30050819. PMID 23245604. S2CID 1541253.

^ Patte C, Bleyer A, Cairo MS (2007). "Non-Hodgkin Lymphoma".  In Bleyer WA, Barr RD (eds.). Cancer in Adolescents and Young Adults (Pediatric Oncology). Springer. p. 129. doi:10.1007/978-3-540-68152-6_9. ISBN 978-3-540-40842-0.

^ "Non-Hodgkin Lymphoma Overview". lymphoma.org.au. 2019. Retrieved 24 August 2019.

^ "Canadian Cancer Statistics". www.cancer.ca. Retrieved 8 February 2018.

^ "Non-hodgkin lymphoma statistics". Cancer Research UK. 14 May 2015. Retrieved 24 August 2019.

^ "Cancer Stat Facts: Non-Hodgkin Lymphoma". National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Retrieved 24 August 2019.

^ "Key Statistics for Non-Hodgkin Lymphoma". www.cancer.org. Retrieved 24 August 2019.


External links[edit]
Non-Hodgkin Lymphoma at American Cancer Society
Non-Hodgkins Lymphoma from Cancer.net (American Society of Clinical Oncology)
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}ClassificationDICD-10: C82-C85ICD-9-CM: 200, 202ICD-O: 9591/3OMIM: 605027MeSH: D008228DiseasesDB: 9065External resourcesMedlinePlus: 000581eMedicine: med/1363 ped/1343Patient UK: Non-Hodgkin lymphomaNCI: Non-Hodgkin lymphoma
.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteLeukaemias, lymphomas and related diseaseB cell(lymphoma,leukemia)(most CD19
CD20)Bydevelopment/markerTdT+
ALL (Precursor B acute lymphoblastic leukemia/lymphoma)
CD5+
naive B cell (CLL/SLL)
mantle zone (Mantle cell)
CD22+
Prolymphocytic
CD11c+ (Hairy cell leukemia)
CD79a+
germinal center/follicular B cell (Follicular
Burkitt's
GCB DLBCL
Primary cutaneous follicle center lymphoma)
marginal zone/marginal zone B-cell (Splenic marginal zone
MALT
Nodal marginal zone
Primary cutaneous marginal zone lymphoma)
RS (CD15+, CD30+)
Classic Hodgkin lymphoma (Nodular sclerosis)
CD20+ (Nodular lymphocyte predominant Hodgkin lymphoma)
PCDs/PP(CD38+/CD138+)
see immunoproliferative immunoglobulin disorders
By infection
KSHV (Primary effusion)
EBV
Lymphomatoid granulomatosis
Post-transplant lymphoproliferative disorder
Classic Hodgkin lymphoma
Burkitt's lymphoma
HCV
Splenic marginal zone lymphoma
HIV (AIDS-related lymphoma)
Helicobacter pylori (MALT lymphoma)
Cutaneous
Diffuse large B-cell lymphoma
Intravascular large B-cell lymphoma
Primary cutaneous marginal zone lymphoma
Primary cutaneous immunocytoma
Plasmacytoma
Plasmacytosis
Primary cutaneous follicle center lymphoma
T/NKT cell(lymphoma,leukemia)(most CD3
CD4
CD8)Bydevelopment/marker
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma)
prolymphocyte (Prolymphocytic)
CD30+ (Anaplastic large-cell lymphoma
Lymphomatoid papulosis type A)
CutaneousMF+variants
indolent: Mycosis fungoides
Pagetoid reticulosis
Granulomatous slack skin
aggressive: Sézary disease

Adult T-cell leukemia/lymphoma
Non-MF
CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
Pleomorphic T-cell lymphoma
Lymphomatoid papulosis type B
CD30+: CD30+ cutaneous T-cell lymphoma
Secondary cutaneous CD30+ large-cell lymphoma
Lymphomatoid papulosis type A
Otherperipheral
Hepatosplenic
Angioimmunoblastic
Enteropathy-associated T-cell lymphoma
Peripheral T-cell lymphoma not otherwise specified (Lennert lymphoma)
Subcutaneous T-cell lymphoma
By infection
HTLV-1 (Adult T-cell leukemia/lymphoma)
NK cell/(most CD56)
Aggressive NK-cell leukemia
Blastic NK cell lymphoma
T or NK
EBV (Extranodal NK-T-cell lymphoma/Angiocentric lymphoma)
Large granular lymphocytic leukemia
Lymphoid+myeloid
Acute biphenotypic leukaemia
Lymphocytosis
Lymphoproliferative disorders (X-linked lymphoproliferative disease
Autoimmune lymphoproliferative syndrome)
Leukemoid reaction
Diffuse infiltrative lymphocytosis syndrome
Cutaneous lymphoid hyperplasia
Cutaneous lymphoid hyperplasia
with bandlike and perivascular patterns
with nodular pattern
Jessner lymphocytic infiltrate of the skin
General
Hematological malignancy
leukemia
Lymphoproliferative disorders
Lymphoid leukemias

Authority control General
Integrated Authority File (Germany)
National libraries
France (data)






